Recently,2023 Xipu ConferenceOfficially Released to the PublicConference Theme：Dual Synergy Reshapes the Industry—Ushering in a New Era of Personal Health Responsibility。It is reported that,The conference is scheduled to be held in Boao, Hainan, China from August 9 to 14.。

"Everyone is the primary person responsible for their own health," a unique public health education campaign that unfolded over three years of the pandemic in China.

According to the World Health Organization, biological factors account for 15%, environmental factors for 17%, and healthcare services for 8% of the determinants of human health, while personal behavior and lifestyle contribute as much as 60%. China has long enshrined the principle that “individuals are the primary stakeholders responsible for their own health” as a core provision in the Basic Healthcare and Health Promotion Law of the People’s Republic of China, which was adopted by vote on December 28, 2019.

The completion of legislation, the popularization of legal knowledge, and the gradual establishment of supporting safeguard systems signify that the implementation of the Healthy China national strategy has entered a new era emphasizing individuals’ primary responsibility for their own health.

With the implementation of the Healthy China strategy, the model centered on disease treatment is gradually transitioning to one focused on health, leading to significant changes in the health industry. According to data from Zhongkang CMH, first, the scale of the health industry will continue to expand to RMB 16 trillion by 2030, with a compound annual growth rate (CAGR) of 6.8%, which is 2–3 percentage points higher than the GDP growth rate during the same period. Second, structurally, the proportion of medical services and medical products centered on disease treatment will decrease from over 90% currently to less than 60%, growing at a CAGR of approximately 5%, with the industry scale expected to reach RMB 9.6 trillion by 2030. The scale of industries centered on health risk management, such as disease prevention, health promotion, and chronic disease management, will reach RMB 6.4 trillion by 2030, with a CAGR of 9.8% from 2025 to 2030. Third, focusing on the development of the pharmaceutical industry, supply chain autonomy and original innovation have become the main themes of industry development; by 2030, the market share of innovative drugs will increase from less than 20% currently to around 50%.

At that time,China’s health industry will evolve into two distinct markets—one for suppliers and one for payers—to address two markedly different types of demand, representing the dual-track development path of the health industry:The government-led, public-welfare-oriented medical security system emphasizes equity and primarily serves the treatment and rehabilitation stages of diseases. With basic medical insurance as the primary payer, it focuses on broad coverage and essential care. The bargaining power of payers continues to strengthen, and centralized volume-based procurement has become normalized; therefore, most players should adhere to the survival principle of cost leadership. In contrast, consumer-driven healthcare sectors—including special-needs medical services, health management, nutritional supplements, Traditional Chinese Medicine (TCM) wellness, and elderly care—are dominated by private institutions operating under market mechanisms. These sectors emphasize efficiency and primarily cater to specialized medical needs and preventive care demands, with individuals and commercial health insurers as the main payers. Generally not subject to tendering and procurement restrictions, differentiation becomes the key to success for players in these fields. Only through the efficient synergy between government and market forces in the health industry can we build a full-cycle closed loop centered on patient value, integrating treatment with prevention and disease diagnosis with health management, thereby truly achieving lifecycle health management.

The dawn of a new era in which individuals assume primary responsibility for their health acts as the starting pistol, prompting binary synergy to evolve in an intertwined manner across different dimensions and levels. In this process, the structure, business models, and value chains of the health industry will undergo fundamental transformations and be reshaped.

CHIC, the China Health Industry Conference (International) Ecological Congress, is dedicated to “leading industrial innovation and integration.” With “collaboration, innovation, technology, R&D, and capital” as its core themes, it brings together leading enterprises and institutions from both domestic and international markets—including pharmaceuticals, healthcare, health services, and financial insurance—to create a global conference for the health industry. It provides forward-looking and systematic exchanges of ideas and information, facilitating multi-dimensional resource alignment and collaborative interactions from tactical to strategic levels.

It is reported that the West China Pharmaceutical Conference (Xipu Hui) has been successfully held for fifteen sessions since 2008. To date, the conference has integrated multiple functions, including forward-thinking idea exchange, strategic cooperation and communication, high-end industry image presentation, and cross-sector integration. Upholding the "Responsibility and Commitment" spirit of Xipu, it advocates mainstream values in China's health industry and leads industrial transformation, innovation, and ecological integration.